Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Therapy

Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse

Leukemia volume 18, pages 1789–1797 (2004)Cite this article

Abstract

For patients with acute myeloid leukemia (AML) relapsed after allogeneic bone marrow transplantation (BMT), donor leukocyte infusion (DLI) as sole therapy has very limited efficacy. We tested the effects of cytoreductive chemotherapy, followed immediately by G-CSF-primed DLI (chemotherapy followed by DLI, Chemo-DLI), in 16 AML patients who relapsed after allogeneic BMT. In all, 10 of these patients achieved complete remission (CR), four of whom remain alive in CR at a median follow-up of 1488 days after DLI. The 2-year overall survival (OS) for the entire cohort was 31%. The 1-year OS for patients with post-BMT remission of 6 months or longer was 55%, compared with 0% for patients with post-BMT remission of less than 6 months, making post-BMT remission duration the only significant prognostic factor for OS (P=0.015). These findings suggest that Chemo-DLI could induce durable remissions in a proportion of relapsed AML patients with relatively long post-BMT remission duration. All five patients who relapsed after achieving CR with Chemo-DLI relapsed at extramedullary sites in the presence of continuous bone marrow remission, suggesting uneven graft-versus-leukemia effects in different parts of the body. Although our data should be interpreted cautiously considering the limited number of patients, isolated extramedullary relapse seems to be common after Chemo-DLI.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Klein JP et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838–843.

    CAS  PubMed  Google Scholar 

  2. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50–57.

    Article  CAS  PubMed  Google Scholar 

  3. Frassoni F, Barrett AJ, Granena A, Ernst P, Garthon G, Kolb HJ et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the EBMT of 117 cases. Br J Haematol 1988; 70: 317–320.

    Article  CAS  PubMed  Google Scholar 

  4. Mrsic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269–275.

    CAS  PubMed  Google Scholar 

  5. Radich JP, Sanders JE, Buckner CD, Martin PJ, Petersen FB, Bensinger W et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304–313.

    Article  CAS  PubMed  Google Scholar 

  6. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997; 19: 709–719.

    Article  CAS  PubMed  Google Scholar 

  7. Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000; 108: 400–407.

    Article  CAS  PubMed  Google Scholar 

  8. Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E et al. Acute Leukemia Working Party of the European Blood and Marrow Transplant Group. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675–3684.

    Article  CAS  PubMed  Google Scholar 

  9. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  10. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  11. Kolb HJ . Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998; 74 (Suppl 2): 321–329.

    Article  CAS  PubMed  Google Scholar 

  12. Porter DL, Collins Jr RH, Shpilberg O, Drobyski WR, Connors JM, Sproles A et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant 1999; 5: 253–261.

    Article  CAS  PubMed  Google Scholar 

  13. Dermime S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ . Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 989–999.

    Article  CAS  PubMed  Google Scholar 

  14. Brouwer RE, van der Heiden P, Schreuder GM, Mulder A, Datema G, Anholts JD et al. Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 2002; 63: 200–210.

    Article  CAS  PubMed  Google Scholar 

  15. Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A et al. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 1996; 5: 115–124.

    Article  CAS  PubMed  Google Scholar 

  16. Hirano N, Takahashi T, Takahashi T, Ohtake S, Hirashima K, Emi N et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10: 1168–1176.

    CAS  PubMed  Google Scholar 

  17. Brouwer RE, Hoefnagel J, Borger van Der Burg B, Jedema I, Zwinderman KH, Starrenburg IC et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol 2001; 115: 298–308.

    Article  CAS  PubMed  Google Scholar 

  18. Bergmann L, Schui DK, Brieger J, Weidmann E, Mitrou PS, Hoelzer D . The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1. Exp Hematol 1995; 23: 1574–1580.

    CAS  PubMed  Google Scholar 

  19. Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG et al. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: a mechanism of tumor immune escape in leukemia patients. Blood 1999; 94: 3135–3140.

    CAS  PubMed  Google Scholar 

  20. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318.

    CAS  PubMed  Google Scholar 

  21. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  22. Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998; 22: 1057–1063.

    Article  CAS  PubMed  Google Scholar 

  23. Keil F, Prinz E, Kalhs P, Lechner K, Moser K, Schwarzinger I et al. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. Leukemia 2001; 15: 355–361.

    Article  CAS  PubMed  Google Scholar 

  24. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405–412.

    Article  CAS  PubMed  Google Scholar 

  25. Lee JH, Lee KH, Kim S, Seol M, Kim SH, Kim WK et al. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. Leukemia Res 2001; 25: 305–312.

    Article  CAS  Google Scholar 

  26. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 607–612.

    Article  CAS  PubMed  Google Scholar 

  27. Lee KH, Lee JH, Choi SJ, Kim S, Lee JS, Kim SH et al. Randomized comparison of two different schedules of granulocyte colony-stimulating factor administration after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24: 591–599.

    Article  CAS  PubMed  Google Scholar 

  28. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  29. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  30. Choi SJ, Lee KH, Lee JH, Kim S, Chung HJ, Lee JS et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 2000; 26: 327–332.

    Article  CAS  PubMed  Google Scholar 

  31. Lee KH, Lee JH, Choi SJ, Lee JH, Kim S, Seol M et al. Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2003; 32: 423–431.

    Article  PubMed  Google Scholar 

  32. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB . Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360–2367.

    CAS  PubMed  Google Scholar 

  33. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL . Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204–3213.

    CAS  PubMed  Google Scholar 

  34. Johnson BD, Drobyski WR, Truitt RL . Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993; 11: 329–336.

    CAS  PubMed  Google Scholar 

  35. Johnson BD, Truitt RL . Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995; 85: 3302–3312.

    CAS  PubMed  Google Scholar 

  36. Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK . High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 147–152.

    Article  CAS  PubMed  Google Scholar 

  37. Chong G, Byrnes G, Szer J, Grigg A . Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy. Bone Marrow Transplant 2000; 26: 1011–1015.

    Article  CAS  PubMed  Google Scholar 

  38. Berthou C, Leglise MC, Herry A, Balcon D, Hardy E, Lessard M et al. Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. Leukemia 1998; 12: 1676–1681.

    Article  CAS  PubMed  Google Scholar 

  39. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Mehta J . Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leukemia Lymphoma 1999; 32: 505–512.

    Article  CAS  PubMed  Google Scholar 

  40. Butcher EC, Picker LJ . Lymphocyte homing and homeostasis. Science 1996; 272: 60–66.

    Article  CAS  PubMed  Google Scholar 

  41. Simpson DR, Nevill TJ, Shepherd JD, Fung HC, Horsman DE, Nantel SH et al. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone Marrow Transplant 1998; 22: 259–264.

    Article  CAS  PubMed  Google Scholar 

  42. Lee KH, Lee JH, Choi SJ, Lee JH, Kim S, Seol M et al. Bone marrow versus extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical course. Bone Marrow Transplant 2003; 32: 835–842.

    Article  CAS  PubMed  Google Scholar 

  43. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204.

    CAS  PubMed  Google Scholar 

  44. Mehta J, Powles R, Singhal S, Tait D, Swansbury J, Treleaven J . Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 16: 133–137.

    CAS  PubMed  Google Scholar 

  45. Nadal E, Fowler A, Kanfer E, Apperley J, Goldman J, Dazzi F . Adjuvant interleukin-2 therapy for patients refractory to donor lymphocyte infusions. Exp Hematol 2004; 32: 218–223.

    Article  CAS  PubMed  Google Scholar 

  46. Frick J, Ritch PS, Hansen RM, Anderson T . Successful treatment of meningeal leukemia using systemic high-dose cytosine arabinoside. J Clin Oncol 1984; 2: 365–368.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    S-J Choi, J-H Lee, J-H Lee, S Kim, M Seol, Y-S Lee, J-S Lee, W-K Kim & K-H Lee

  2. Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    H-S Chi

Authors
  1. S-J Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J-H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J-H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Seol
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y-S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J-S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W-K Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H-S Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K-H Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S-J Choi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, SJ., Lee, JH., Lee, JH. et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 18, 1789–1797 (2004). https://doi.org/10.1038/sj.leu.2403523

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403523

Keywords

This article is cited by

Search

Advanced search

Quick links